These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12694247)

  • 1. Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma.
    Vincent T; Molina L; Espert L; Mechti N
    Br J Haematol; 2003 Apr; 121(2):259-69. PubMed ID: 12694247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein.
    Vincent T; Jourdan M; Sy MS; Klein B; Mechti N
    J Biol Chem; 2001 May; 276(18):14728-36. PubMed ID: 11278272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone.
    Grigorieva I; Thomas X; Epstein J
    Exp Hematol; 1998 Jul; 26(7):597-603. PubMed ID: 9657134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells.
    Ohwada C; Nakaseko C; Koizumi M; Takeuchi M; Ozawa S; Naito M; Tanaka H; Oda K; Cho R; Nishimura M; Saito Y
    Eur J Haematol; 2008 Mar; 80(3):245-50. PubMed ID: 18081709
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
    Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
    FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
    Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
    Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular matrix in bone marrow can mediate drug resistance in myeloma.
    Vincent T; Mechti N
    Leuk Lymphoma; 2005 Jun; 46(6):803-11. PubMed ID: 16019524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms.
    Nefedova Y; Landowski TH; Dalton WS
    Leukemia; 2003 Jun; 17(6):1175-82. PubMed ID: 12764386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis.
    Frassanito MA; Cusmai A; Iodice G; Dammacco F
    Blood; 2001 Jan; 97(2):483-9. PubMed ID: 11154226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells.
    Hönemann D; Chatterjee M; Savino R; Bommert K; Burger R; Gramatzki M; Dörken B; Bargou RC
    Int J Cancer; 2001 Sep; 93(5):674-80. PubMed ID: 11477577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal cytokine production by bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells.
    Zdzisińska B; Bojarska-Junak A; Dmoszyńska A; Kandefer-Szerszeń M
    Arch Immunol Ther Exp (Warsz); 2008; 56(3):207-21. PubMed ID: 18512025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell death.
    Voorhees PM; Chen Q; Small GW; Kuhn DJ; Hunsucker SA; Nemeth JA; Orlowski RZ
    Br J Haematol; 2009 May; 145(4):481-90. PubMed ID: 19344406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
    Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
    Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.
    Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE
    Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
    Gazitt Y; Fey V; Thomas C; Alvarez R
    Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines.
    Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE
    Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA NEAT1 promotes dexamethasone resistance in multiple myeloma by targeting miR-193a/MCL1 pathway.
    Wu Y; Wang H
    J Biochem Mol Toxicol; 2018 Jan; 32(1):. PubMed ID: 29205703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
    Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
    Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
    Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
    Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone.
    Puthier D; Bataille R; Barillé S; Mellerin MP; Harousseau JL; Ponzio A; Robillard N; Wijdenes J; Amiot M
    Blood; 1996 Dec; 88(12):4659-66. PubMed ID: 8977259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.